Skip to content
News
News
May 1, 2026
Mabwell Therapeutics Announces Publication of Preclinical Data on Differentiated TREM2 Agonist Antibody 03O05 in Journal of Neuroinflammation
Read More
October 3, 2025
Mabwell Therapeutics Receives FDA IND Clearance to Initiate Clinical Trials for MWTX-4611 to Treat Alzheimer’s Disease
Read More
September 24, 2025
Mabwell Therapeutics Announces First Patient Dosed in U.S. Phase II Study of MWTX-003 (DISC-3405)
Read More
June 13, 2024
Mabwell Presents First-in-Human Clinical Data of MWTX-003 (9MW3011) at EHA 2024
Read More
February 9, 2024
FDA Grants Orphan Drug Designation to MWTX-003 (DISC-3405) for the Treatment of Polycythemia Vera
Read More
September 20, 2023
FDA Grants Fast Track Designation to MWTX-003 for Polycythemia Vera
Read More
July 16, 2023
Mabwell Therapeutics Presents Preclinical Data on Novel Anti-Amyloid Beta Oligomer Antibody at AAIC 2023
Read More
March 13, 2023
Mabwell Doses First Subject in First-in-Human Trial of MWTX-003 (9MW3011)
Read More
January 20, 2023
Mabwell Therapeutics Announces Exclusive Licensing Agreement with Disc Medicine for Novel Hematologic Drug Candidates
Read More
About
Science
Platform
Pipeline
News
Careers
Contact
Linkedin-in
